A total of 5 analyst ratings have been received for Zevra Therapeutics, with the consensus rating being Buy. The average one-year price target stands at $22.0, suggesting a potential 179.54% upside.

Analysts expect Eton Pharmaceuticals to report an earnings per share (EPS) of $0.03. The announcement from Eton ...

One of the cannabis companies trying mightily to succeed is Tilray Brands (NASDAQ: TLRY), which shed more than 26% of its ...

Tilray Brands (NasdaqGS:TLRY) launched a new beverage line, "Cruisies," focusing on ready-to-drink cocktails. This product-related announcement coincided with a period when Tilray's shares rose 10%, ...

With election results in and earnings season heating up, several factors could sway TSX stocks in today’s session.

Tilray Brands missed Q3 expectations but improved its balance sheet, with net debt at $14 million. Read why I maintain my strong buy rating on TLRY stock.

Tilray Brands, Inc. (NASDAQ ... stock that is more promising than TLRY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best ...

Adjusted earnings are expected to come in at $1.61 ... beating analysts’ expectations by 1.9%, and Tilray reported a revenue decline of 1.4%, falling short of estimates by 10.1%.

The firm has a market capitalization of $421.94 million, a price-to-earnings ratio of -1.50 and a beta of 1.88. Tilray (NASDAQ:TLRY – Get Free Report) last issued its quarterly earnings results ...

In other recent news, Tilray Inc. reported its third-quarter 2025 financial results, revealing a significant revenue miss and a larger-than-expected net loss. The company’s earnings per share came in ...